Antimalarial treatments more likely to fail in children with acute malnutrition
13 March 2024
Children with acute malnutrition across Africa and Asia have a higher risk of treatment failure and malaria reinfection, even after being given the best currently available and recommended malaria treatment. Researchers from the Infectious Diseases Data Observatory (IDDO) at Oxford University analysed data from over 11,000 young children for this study, published in Lancet Global Health.
The analysis found that children younger than age five who were very underweight for their height had nearly double the risk of malaria treatment failing, even when given the World Health Organisation recommended doses of an artemisinin-based combination therapy. This is currently the best treatment for falciparum malaria.
47 million children across the world are estimated to suffer from acute malnutrition, with a 30% increase in the last three years (an additional 13.6 million children). Areas with malnutrition overlap with those affected by malaria across many tropical and sub-tropical parts of the world, and children under five account for 80% of all malaria deaths.
The results from the research study suggest that acute malnutrition in children may play a role not only in treatment failure, but it also puts this vulnerable group at higher risk of severe malaria and death.
“Malaria and malnutrition both affect poorer communities with limited research resources, so there just aren’t enough studies on the efficacy of antimalarial drugs in malnourished children, and past studies have contradictory results,” said Professor Philippe Guerin, study lead and Director of the Infectious Diseases Data Observatory. “So we used a different strategy to answer this question.”
The research team pooled individual patient data from 36 different antimalarial efficacy studies from 24 countries, that included both height and weight information for the study participants.
“No one individual study included a large enough sample of malnourished children to uncover a clear relationship, but by combining information across many different studies, which each included few malnourished children, we were able to spot a clear pattern,” said Dr Kasia Stepniewska, the IDDO Head of Statistics.
“These results highlight the power of pooling and reusing data from clinical studies of poverty-related diseases across Asia, Africa and the Americas,” said study author Professor Karen Barnes, Head of WWARN’s Africa Hub and the Pharmacology Scientific Group at the University of Cape Town, South Africa. The Infectious Diseases Data Observatory has one of the biggest data repositories of this kind for tropical and infectious diseases, which is free to use for researchers across the world.
The study’s conclusions also urge scientists and doctors to record young children’s height and weight in future malaria studies, to identify children who need more careful medical follow-up because malaria treatment is more likely to fail. Future work is also now needed to optimise the dose of current anti-malarial drugs for this group of children.
Notes for editors
For more information, including to arrange researcher interviews and to arrange for a copy for the research paper, please email (University News Office email: [email protected]).
Chris McIntyre: Communications Manager (Research and Innovation)
tel (direct): 01865 270 046 or tel (News Office): 01865 280528
[email protected]
About the Infectious Diseases Data Observatory
The Infectious Diseases Data Observatory (IDDO) exists to promote the reuse of individual participant data across the global infectious disease community. IDDO curates submitted data from many different sources in-house, to produce freely available harmonised datasets, enabling scientists to answer new research questions from existing data.
It also provides the methods, governance and infrastructure to translate clinical data into evidence to improve health outcomes worldwide. IDDO incorporates the pioneering WorldWide Antimalarial Resistance Network (WWARN), a collaborative data-sharing framework that proved it is possible to produce policy-changing scientific evidence from pooling existing data. Find out more on iddo.org/research-themes.
About the University of Oxford
Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the eighth year running, and number 3 in the QS World Rankings 2024. At the heart of this success are the twin-pillars of our ground-breaking research and innovation and our distinctive educational offer.
Oxford is world-famous for research and teaching excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research alongside our personalised approach to teaching sparks imaginative and inventive insights and solutions.
Through its research commercialisation arm, Oxford University Innovation, Oxford is the highest university patent filer in the UK and is ranked first in the UK for university spinouts, having created more than 300 new companies since 1988. Over a third of these companies have been created in the last five years. The university is a catalyst for prosperity in Oxfordshire and the United Kingdom, contributing £15.7 billion to the UK economy in 2018/19, and supports more than 28,000 full time jobs.